FIELD: biotechnology.
SUBSTANCE: invention refers to biotechnology, namely to compounds capable of binding vascular endothelium growth factor (VEGF), and can be used in medicine.
EFFECT: said compounds are spiral peptides characterized by presence of amino acid sequence C in certain positions α-tetrasubstituted amino acid, in particular, α-aminoisobutanoic acid, which promotes intensification of binding with VEGF, and also increases resistance of peptides to enzymatic splitting.
1 cl, 3 tbl, 28 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATES OF PEPTIDE AND POLYAMINO ACID, BINDING VESSEL ENDOTHELIUM GROWTH FACTOR | 2020 |
|
RU2781974C2 |
| PEPTIDE DRUGS WITH HIGH EFFECTIVENESS AGAINST INSULIN RESISTANCE | 2012 |
|
RU2602801C2 |
| ANALOGUES OF GHRELIN SUBSTITUTED AT N-END | 2007 |
|
RU2459831C2 |
| ANTIANGIOGENIC COMPOUNDS | 2009 |
|
RU2511420C2 |
| GLUCAGON ANALOGUES, POSSESSING HIGHER SOLUBILITY AND STABILITY IN BUFFERS WITH PHYSIOLOGICAL Ph VALUES | 2009 |
|
RU2560254C2 |
| GHRELIN ANALOGUES | 2006 |
|
RU2427587C2 |
| PEPTIDES OF DIRECTED ACTION OF VEGFR-1/NRP-1 | 2008 |
|
RU2488592C2 |
| BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES | 2014 |
|
RU2640253C2 |
| MODIFIED BINDING PROTEINS, INHIBITING INTERACTION OF VEGF-A RECEPTOR | 2011 |
|
RU2605309C2 |
| CYCLOPEPTIDES, METHOD FOR PRODUCTION THEREOF AND USES AS ANGIOGENESIS INHIBITORS OR ACTIVATORS | 2001 |
|
RU2249599C2 |
